Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q1

2372.TEDINET S100OU1N
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥4.8bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥15.7bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥3.4bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥1.4bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥354m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.4bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥2.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥439m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.5bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥440m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥258m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥255m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥28.2bnat 2022-06-30Cons.Assets
Total assets¥26.6bnat 2022-03-31Cons.Assets
Total assets¥21.8bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥17.2bnat 2022-06-30Cons.Liabilities
Total liabilities¥16.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥11.0bnat 2022-06-30Cons.Net assets
Net assets / equity¥10.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥8.6bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥5.9bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥6.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥88.372022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥162.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.482021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥88.222022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥162.172021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥21.422021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio38.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥45m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥357m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥357m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥364m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue2022-04-01 → 2022-06-30¥385m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue external2022-04-01 → 2022-06-30¥374m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥10m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentsegment profit2022-04-01 → 2022-06-30¥42m
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-06-30¥1.3bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.3bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥75m
jpcrp040300-q1r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-06-30¥61m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-06-30¥468m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-06-30¥241m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥226m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-06-30¥36m
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥24m
jpcrp040300-q1r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
—segment totalrevenue2022-04-01 → 2022-06-30¥5.1bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥337m
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥357m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥6m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥60m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥217m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥217m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥303m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue2021-04-01 → 2021-06-30¥166m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue external2021-04-01 → 2021-06-30¥164m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1m
jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segmentsegment profit2021-04-01 → 2021-06-30−¥162m
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue2021-04-01 → 2021-06-30¥1.1bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.1bn
jpcrp040300-q1r_E05352-000CROreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥16m
jpcrp040300-q1r_E05352-000CROreportable segmentsegment profit2021-04-01 → 2021-06-30¥71m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue2021-04-01 → 2021-06-30¥390m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue external2021-04-01 → 2021-06-30¥228m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥161m
jpcrp040300-q1r_E05352-000Medical Supportreportable segmentsegment profit2021-04-01 → 2021-06-30¥21m
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05352-000SMOreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥35m
jpcrp040300-q1r_E05352-000SMOreportable segmentsegment profit2021-04-01 → 2021-06-30¥787m
—segment totalrevenue2021-04-01 → 2021-06-30¥3.6bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥3.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥215m
—segment totalsegment profit2021-04-01 → 2021-06-30¥717m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥3.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥217m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥657m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 404
ItemContextValueUnit
Capital surplusPrior1YearInstant1466000000JPY
Capital surplusCurrentQuarterInstant1464000000JPY
Retained earningsPrior1YearInstant5099000000JPY
Retained earningsCurrentQuarterInstant5864000000JPY
Treasury stockPrior1YearInstant-423000000JPY
Treasury stockCurrentQuarterInstant-423000000JPY
Shareholders equityPrior1YearInstant10021000000JPY
Shareholders equityCurrentQuarterInstant10785000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant68000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant117000000JPY
Foreign currency translation adjustmentPrior1YearInstant38000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant56000000JPY
Valuation and translation adjustmentsPrior1YearInstant107000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant173000000JPY
Subscription rights to sharesPrior1YearInstant17000000JPY
Subscription rights to sharesCurrentQuarterInstant16000000JPY
Non controlling interestsPrior1YearInstant16000000JPY
Non controlling interestsCurrentQuarterInstant20000000JPY
Net assetsPrior1YearInstant10162000000JPY
Net assetsCurrentQuarterInstant10996000000JPY
Liabilities and net assetsPrior1YearInstant26588000000JPY
Liabilities and net assetsCurrentQuarterInstant28173000000JPY
Net salesPrior1YTDDuration3388000000JPY
Net salesCurrentYTDDuration4792000000JPY
Cost of salesPrior1YTDDuration1945000000JPY
Cost of salesCurrentYTDDuration2129000000JPY
Gross profitPrior1YTDDuration1442000000JPY
Gross profitCurrentYTDDuration2662000000JPY
Directors compensations sgaPrior1YTDDuration120000000JPY
Directors compensations sgaCurrentYTDDuration117000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration360000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration507000000JPY
Commission fee sgaPrior1YTDDuration45000000JPY
Commission fee sgaCurrentYTDDuration48000000JPY
Rent expenses sgaPrior1YTDDuration93000000JPY
Rent expenses sgaCurrentYTDDuration101000000JPY
Research and development expenses sgaPrior1YTDDuration181000000JPY
Research and development expenses sgaCurrentYTDDuration100000000JPY
Other sgaPrior1YTDDuration286000000JPY
Other sgaCurrentYTDDuration338000000JPY
Selling general and administrative expensesPrior1YTDDuration1088000000JPY
Selling general and administrative expensesCurrentYTDDuration1213000000JPY
Operating incomePrior1YTDDuration354000000JPY
Operating incomeCurrentYTDDuration1449000000JPY
Interest income noiPrior1YTDDuration10000000JPY
Interest income noiCurrentYTDDuration1000000JPY
Dividends income noiPrior1YTDDuration2000000JPY
Dividends income noiCurrentYTDDuration0JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration204000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass